Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01464879 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator
A Phase 2 study of Hypogonadal Males, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01464879: Completed Phase 2 study of Hypogonadal Males, sponsored by Ferring Pharmaceuticals.
NCT01464879 is a Phase 2 study of Hypogonadal Males that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01464879, a Phase 2 study of Hypogonadal Males, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2 clinical trial in adult hypogonadal males with baseline morning serum testosterone concentrations \<300 ng/dL. The purpose of this study is to evaluate the pharmacokinetics of FE 999303, delivered using an applicator in comparison to hand application
Primary Outcome
Descriptive statistics was used to present the outcome results.
Conditions Studied
Interventions
- DRUG Testosterone Gel (FE 999303)
Study Locations (1)
New York
- AccuMed Research Associates - Garden City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
What the finished NCT01464879 record still lists
NCT01464879 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Hypogonadal Males appearing as the primary indexed condition, and to 1 intervention - of which Testosterone Gel (FE 999303) is the first listed.
NCT01464879 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01464879 about?
NCT01464879 is a clinical study titled "A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator". This is a Phase 2 clinical trial in adult hypogonadal males with baseline morning serum testosterone concentrations \<300 ng/dL. The purpose of this study is to evaluate the pharmacokinetics of FE 999303, delivered using an applicator in comparison to hand application
What is the current status of trial NCT01464879?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-12. Estimated completion is 2012-05.
What conditions does trial NCT01464879 study?
This clinical trial studies the following conditions: Hypogonadal Males.
What interventions are being tested in trial NCT01464879?
The interventions under investigation include: Testosterone Gel (FE 999303) (DRUG).
Who is sponsoring clinical trial NCT01464879?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01464879 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadal Males
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01464879's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia